Vabomere, Through the Centralised Procedure Under Article 3 (2) (A) of Regulation (EC) No 726/2004

Total Page:16

File Type:pdf, Size:1020Kb

Vabomere, Through the Centralised Procedure Under Article 3 (2) (A) of Regulation (EC) No 726/2004 20 September 2018 EMA/CHMP/700663/2018 Committee for Medicinal Products for Human Use (CHMP) Assessment report Vabomere International non-proprietary name: meropenem / vaborbactam Procedure No. EMEA/H/C/004669/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Background information on the procedure .............................................. 7 1.1. Submission of the dossier ...................................................................................... 7 1.2. Steps taken for the assessment of the product ......................................................... 8 2. Scientific discussion .............................................................................. 10 2.1. Problem statement ............................................................................................. 10 2.1.1. Disease or condition ......................................................................................... 10 2.1.2. Epidemiology .................................................................................................. 10 2.1.3. Aetiology and pathogenesis .............................................................................. 10 2.1.4. Clinical presentation, diagnosis .......................................................................... 11 2.1.5. Management ................................................................................................... 11 2.2. Quality aspects .................................................................................................. 12 2.2.1. Introduction .................................................................................................... 12 2.2.2. Active Substance ............................................................................................. 12 2.2.3. Finished Medicinal Product ................................................................................ 16 2.2.4. Discussion on chemical, pharmaceutical and biological aspects .............................. 19 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects ...................... 20 2.2.6. Recommendations for future quality development................................................ 20 2.3. Non-clinical aspects ............................................................................................ 21 2.3.1. Introduction .................................................................................................... 21 2.3.2. Pharmacology ................................................................................................. 21 2.3.3. Pharmacokinetics............................................................................................. 22 2.3.4. Toxicology ...................................................................................................... 25 2.3.5. Ecotoxicity/environmental risk assessment ......................................................... 30 2.3.6. Discussion on non-clinical aspects...................................................................... 32 2.3.7. Conclusion on the non-clinical aspects ................................................................ 33 2.4. Clinical aspects .................................................................................................. 33 2.4.1. Introduction .................................................................................................... 33 2.4.2. Pharmacokinetics............................................................................................. 40 2.4.3. Pharmacodynamics .......................................................................................... 50 2.4.4. Discussion on clinical pharmacology ................................................................... 60 2.4.5. Conclusions on clinical pharmacology ................................................................. 64 2.5. Clinical efficacy .................................................................................................. 65 2.5.1. Main studies ................................................................................................... 65 2.5.2. Discussion on clinical efficacy ............................................................................ 81 2.5.3. Conclusions on the clinical efficacy ..................................................................... 84 2.6. Clinical safety .................................................................................................... 85 2.6.1. Discussion on clinical safety .............................................................................. 97 2.6.2. Conclusions on the clinical safety ....................................................................... 97 2.7. Risk Management Plan ........................................................................................ 97 2.8. Pharmacovigilance .............................................................................................. 99 2.9. New Active Substance ......................................................................................... 99 Assessment report EMA/CHMP/700663/2018 Page 2/108 2.10. Product information ........................................................................................ 100 2.10.1. User consultation ......................................................................................... 100 2.10.2. Additional monitoring ................................................................................... 100 3. Benefit-Risk Balance............................................................................ 101 3.1. Therapeutic Context ......................................................................................... 101 3.1.1. Disease or condition ....................................................................................... 101 3.1.2. Available therapies and unmet medical need ..................................................... 101 3.1.3. Main clinical studies ....................................................................................... 102 3.2. Favourable effects ............................................................................................ 102 3.3. Uncertainties and limitations about favourable effects ........................................... 103 3.4. Unfavourable effects ......................................................................................... 104 3.5. Uncertainties and limitations about unfavourable effects ....................................... 104 3.6. Effects Table .................................................................................................... 105 3.7. Benefit-risk assessment and discussion ............................................................... 105 3.7.1. Importance of favourable and unfavourable effects ............................................ 105 3.7.2. Balance of benefits and risks ........................................................................... 106 3.7.3. Additional considerations on the benefit-risk balance ......................................... 106 3.8. Conclusions ..................................................................................................... 106 4. Recommendations ............................................................................... 106 Assessment report EMA/CHMP/700663/2018 Page 3/108 List of abbreviations AM Alveolar Macrophages AmpC hyper AmpC hyperproducer ANOVA Analysis of variance AP Acute Pyelonephritis AST Antimicrobial susceptibility testing AUC0-inf Area under the plasma concentration-time curve from time zero to infinity AUC0-8 Area under the plasma concentration-time curve from 0 to 8 hours AUC0-24 Area under the concentration-time curve from 0 to 24 hours AUC0-t Area under the plasma concentration-time curve time zero to the last measurable concentration AUC:MIC Area under the concentration-time curve (AUC) to MIC AVI Avibactam AZT Aztreonam BAL Bronchoalveolar Lavage BAT Best Available Therapy BLI Beta-lactamase inhibitor BSA Body surface area CAMHB Cation-adjusted Mueller-Hinton broth CAZ Ceftazidime CEP Certificate of Suitability of the European Pharmacopoeia CDC Center for Disease Control and Prevention CFU Colony forming units CI Confidence Interval cIAI Complicated intra-abdominal infections CLcr Creatinine clearance CLd Distributional clearance CLnr Non-renal clearance CLR Renal clearance CLSI Clinical and Laboratory Standards Institute CLt Plasma clearance Cmax Maximum drug concentration CRE Carbapenem-Resistant Enterobacteriaceae cUTI Complicated Urinary Tract Infection CV% Percent coefficient of variation CYP450 Cytochrome P450 DSC Differential Scanning Calorimetry ECG Electrocardiogram eGFR Estimated glomerular filtration ELF Epithelial Lining Fluid Emax Sigmoid maximum reduction EOIVT End of intravenous treatment EOT End of treatment ESBLs Extended-spectrum beta-lactamases ESRD End-stage renal disease EUCAST European Committee on Antimicrobial Susceptibility Testing FDA Food and Drug Administration fe0-8 Percentage of dose excreted in the urine over 8 hours FL Full-length FME Frequencies of mutant emergence g Grams GC-FID Gas Chromatography- Flame Ionization Detector Assessment
Recommended publications
  • Formerly VNRX-5133) Against a 2122 Palmer Drive 02581 Schaumburg, IL 60173 USA European 2018-2020 Surveillance Collection of Pseudomonas Aeruginosa
    IHMA, Inc. Antimicrobial Activity of Cefepime in Combination with Taniborbactam (formerly VNRX-5133) Against a 2122 Palmer Drive 02581 Schaumburg, IL 60173 USA European 2018-2020 Surveillance Collection of Pseudomonas aeruginosa www.ihma.com M. Hackel1, M. Wise1, D. Sahm1 1IHMA, Inc., Schaumburg, IL, USA INTRODUCTION RESULTS RESULTS SUMMARY Taniborbactam, (formerly VNRX-5133), is a Table 1. In vitro activity of cefepime-taniborbactam and Figure 1. MIC distribution of cefepime, cefepime-taniborbactam, and comparators Figure 3. MIC distribution of cefepime, cefepime-taniborbactam, and comparators . Cefepime-taniborbactam demonstrated potent in vitro activity novel cyclic boronate-based broad-spectrum β- comparator agents against 2,035 P. aeruginosa from against 2,035 Pseudomonas aeruginosa from Europe against 595 meropenem-non-susceptible Pseudomonas aeruginosa from Europe (MIC50/90, 2/8 mg/L; 95.6% inhibited at ≤8 mg/L) against P. lactamase inhibitor with potent and selective Europe aeruginosa isolates from Europe (Table 1). direct inhibitory activity against both serine- and Phenotype (n; percent of total) Antimicrobial %S %I* %R MIC50 MIC90 . Provisional susceptibility rates to cefepime-taniborbactam and All (2,035) Cefepime-taniborbactam 95.6 -- 4.4 2 8 Cefepime (FEP) metallo-β-lactamases (Ambler Classes A, B, C Cefepime 0.0 79.0 21.0 4 32 Cefepime (FEP) Ceftazidime 0.0 75.8 24.2 4 >32 Cefepime-taniborbactam (FTB) FTB 86.6% ≤8 µg/mL ceftolozane-tazobactam, respectively, were 73.2% and 13.2% vs and D). Taniborbactam greatly enhances
    [Show full text]
  • United States Patent ( 10 ) Patent No.: US 10,561,6759 B2 Griffith Et Al
    US010561675B2 United States Patent ( 10 ) Patent No.: US 10,561,6759 B2 Griffith et al. (45 ) Date of Patent : * Feb . 18 , 2020 (54 ) CYCLIC BORONIC ACID ESTER ( 58 ) Field of Classification Search DERIVATIVES AND THERAPEUTIC USES CPC A61K 31/69 ; A61K 31/396 ; A61K 31/40 ; THEREOF A61K 31/419677 (71 ) Applicant: Rempex Pharmaceuticals , Inc. , (Continued ) Lincolnshire , IL (US ) (56 ) References Cited (72 ) Inventors : David C. Griffith , San Marcos, CA (US ) ; Michael N. Dudley , San Diego , U.S. PATENT DOCUMENTS CA (US ) ; Olga Rodny , Mill Valley , CA 4,194,047 A 3/1980 Christensen et al . ( US ) 4,260,543 A 4/1981 Miller ( 73 ) Assignee : REMPEX PHARMACEUTICALS , ( Continued ) INC . , Lincolnshire , IL (US ) FOREIGN PATENT DOCUMENTS ( * ) Notice : Subject to any disclaimer, the term of this EP 1550657 A1 7/2005 patent is extended or adjusted under 35 JP 2003-229277 A 8/2003 U.S.C. 154 ( b ) by 1129 days. (Continued ) This patent is subject to a terminal dis claimer . OTHER PUBLICATIONS Abdel -Magid et al. , “ Reductive Amination ofAldehydes and Ketones ( 21) Appl. No .: 13 /843,579 with Sodium Triacetoxyborohydride: Studies on Direct and Indirect Reductive Amination Procedures ” , J Org Chem . ( 1996 )61 ( 11 ): 3849 ( 22 ) Filed : Mar. 15 , 2013 3862 . (65 ) Prior Publication Data (Continued ) US 2013/0331355 A1 Dec. 12 , 2013 Primary Examiner — Shengjun Wang Related U.S. Application Data (74 ) Attorney, Agent, or Firm — Wilmer Cutler Pickering (60 ) Provisional application No.61 / 656,452 , filed on Jun . Hale and Dorr LLP 6 , 2012 (57 ) ABSTRACT (51 ) Int. Ci. A61K 31/69 ( 2006.01) Method of treating or ameliorating a bacterial infection A61K 31/00 ( 2006.01 ) comprising administering a composition comprising a cyclic (Continued ) boronic acid ester compound in combination with a car ( 52 ) U.S.
    [Show full text]
  • P1157 Searching for Optimal Treatment Regimens For
    P1157 Searching for optimal treatment regimens for Stenotrophomonas maltophilia resistant to levofloxacin and/or sulfamethoxazole-trimethoprim: aztreonam in combination with avibactam or vaborbactam Mark Biagi*1, Samah Qasmieh1, Denise Lamm1, Kevin Meyer1, Tiffany Wu1, Eric Wenzler1 1 Pharmacy Practice, University of Illinois at Chicago, Chicago, United States Background: Current preferred treatment options for Stenotrophomonas maltophilia include sulfamethoxazole- trimethoprim and levofloxacin but their use may be compromised by increasing reports of resistance, toxicities, and drug interactions. Among the β-lactams, only aztreonam is able to evade S. maltophilia’s L1 metallo-β- lactamase-mediated hydrolysis but it remains prone to hydrolysis by the L2 serine β-lactamase, effectively rendering all β-lactams ineffective. Combining aztreonam with a β-lactamase inhibitor with activity against L2 may restore aztreonam’s activity and offer clinicians a novel treatment option. Materials/methods: MICs for 37 clinical S. maltophilia isolates resistant to levofloxacin and/or sulfamethoxazole- trimethoprim were tested in triplicate via broth microdilution method according to CLSI guidelines. Modal MICs are reported. Susceptibility interpretations were based on CLSI breakpoints for levofloxacin and sulfamethoxazole- trimethoprim against S. maltophilia and against Pseudomonas aeruginosa for aztreonam-based regimens. Time kill analyses were performed in triplicate for 5 isolates at standard inoculum (106) for aztreonam, aztreonam/avibactam, and aztreonam/vaborbactam at either fCmax or ¼, ½, 1, 2, or 4x MIC. Bactericidal activity was considered a ≥3 log10 reduction in CFU/mL from the starting inoculum. Synergy was ≥2 log10 reduction in CFU/mL compared to the most active agent alone. Results: Susceptibilities are summarized in Table 1. 97% (36/37) of isolates were resistant to aztreonam.
    [Show full text]
  • 12. What's Really New in Antibiotic Therapy Print
    What’s really new in antibiotic therapy? Martin J. Hug Freiburg University Medical Center EAHP Academy Seminars 20-21 September 2019 Newsweek, May 24-31 2019 Disclosures There are no conflicts of interest to declare EAHP Academy Seminars 20-21 September 2019 Antiinfectives and Resistance EAHP Academy Seminars 20-21 September 2019 Resistance of Klebsiella pneumoniae to Pip.-Taz. olates) EAHP Academy Seminars 20-21 September 2019 https://resistancemap.cddep.org/AntibioticResistance.php Multiresistant Pseudomonas Aeruginosa Combined resistance against at least three different types of antibiotics, 2017 EAHP Academy Seminars 20-21 September 2019 https://atlas.ecdc.europa.eu/public/index.aspx Distribution of ESBL producing Enterobacteriaceae EAHP Academy Seminars 20-21 September 2019 Rossolini GM. Global threat of Gram-negative antimicrobial resistance. 27th ECCMID, Vienna, 2017, IS07 Priority Pathogens Defined by the World Health Organisation Critical Priority High Priority Medium Priority Acinetobacter baumanii Enterococcus faecium Streptococcus pneumoniae carbapenem-resistant vancomycin-resistant penicillin-non-susceptible Pseudomonas aeruginosa Helicobacter pylori Haemophilus influenzae carbapenem-resistant clarithromycin-resistant ampicillin-resistant Enterobacteriaceae Salmonella species Shigella species carbapenem-resistant fluoroquinolone-resistant fluoroquinolone-resistant Staphylococcus aureus vancomycin or methicillin -resistant Campylobacter species fluoroquinolone-resistant Neisseria gonorrhoae 3rd gen. cephalosporin-resistant
    [Show full text]
  • AMR Surveillance in Pharma: a Case-Study for Data Sharingauthor by Professor Barry Cookson
    AMR Open Data Initiative AMR Surveillance in Pharma: a case-study for data sharingauthor by Professor Barry Cookson External Consultant to Project eLibrary • Division of Infection and Immunity, Univ. College London ESCMID• Dept. of Microbiology, © St Thomas’ Hospital Background of “90 day Project” Addressed some recommendations of the first Wellcome funded multi-disciplinary workshop (included Pharma Academia & Public Health invitees: 27thauthor July 2017 (post the Davos Declaration): by 1) Review the landscape of existing Pharma AMR programmes, their protocols,eLibrary data standards and sets 2) Develop a "portal" (register/platform) to access currently available AMR Surveillance data ESCMID Important ©to emphasise that this is a COLLABORATION between Pharma and others Overview of Questionnaire Content • General information - including name,author years active, countries, antimicrobials, microorganisms.by • Methodology - including accreditation, methodology for; surveillance, isolate collection, organism identification, breakpointseLibrary used, • Dataset - including data storage methodology, management and how accessed. ESCMID © 13 Company Responses author 7 by 3 3 eLibrary ESCMID © Structure of register Companies can have different ways of referring to their activities: We had to choose a consistent framework. author Companies Companyby 1 Programmes Programme A Programme B eLibrary Antimicrobials 1 2 3 4 5 company’s product comparator company’s product antimicrobials Programmes canESCMID contain multiple studies (e.g. Pfizer has© single
    [Show full text]
  • Regional Hospitals Antimicrobial Susceptibilities of Major Pathogens
    Comparative Daily Costs for Commonly used Comparative Daily Costs for Commonly Commonly used INTRAVENOUS INTRAVENOUS used ORAL Antibiotics* Antibiotics* Antibiotics* Daily Med Daily Med Intravenous Antibiotics Normal Dose Cost ($) Oral Antibiotics Normal Dose Cost ($) P.O. Box 342 NOTES: Pencillins Penicillins Ampicillin 1 gm q 6h 5.68 Amoxicillin 500 mg tid 0.24 This report summarizes routinely tested antibiotics. Minneapolis, MN 55440-0342 Ampicillin/Sulbactam 3 gm q 6h 14.73 Amoxicillin/Clavulanate 500 mg tid 0.90 Actual patient reports may selectively exclude some 612-863-4678 Nafcillin 1 gm q 4h 19.02 Dicloxacillin 500 mg qid 2.84 susceptibility results. Penicillin G 5 MU q 4h 45.18 Penicillin VK 500 mg qid 0.75 Piperacillin/Tazobactam 3.375 gm q8h 6.54 Cephalosporins 2020 Cephalosporins Cefadroxil 500 mg bid 0.71 Cefazolin 1 gm q 8h 1.98 Cefdinir 300 mg bid 2.64 Regional Hospitals Cefepime 1 gm q 8h 12.94 Cefuroxime axetil 250 mg bid 2.90 Antimicrobial Susceptibilities Ceftazidime 1 gm q 8h 9.05 Cephalexin 500 mg qid 0.30 Ceftazidime/avibactam 2.5 gm q 8h 1075.89 Anaerobic of Major Pathogens Cefoxitin 1 gm q 6h 11.18 Clindamycin 450 mg tid 1.80 Ceftaroline 600 mg q12h 315.62 Metronidazole 500 mg tid 0.46 Data is also located on the Allina Knowledge Network (AKN): Ceftolozane-tazobactam 1.5 gm q 8h 349.83 Miscellaneous Cefriaxone 1 gm q 24h 1.20 Acyclovir 200 mg 5x/d 0.55 http://labs.allinahealth.org/Lab/Linkview?Sublink=susceptdata Cefuroxime 1.5 gm q 8h 11.16 Atovaquone 1500 mg daily 40.38 Carbapenems Azithromycin 250 mg daily 0.66 Ertapenem 1 gm q 24h 54.86 Ciprofloxacin 500 mg bid 0.26 The intent of this card is to provide a preliminary guide to Imipenem 500 mg q 8h 29.82 Clarithromycin 500 mg bid 1.55 susceptibilities.
    [Show full text]
  • Consideration of Antibacterial Medicines As Part Of
    Consideration of antibacterial medicines as part of the revisions to 2019 WHO Model List of Essential Medicines for adults (EML) and Model List of Essential Medicines for children (EMLc) Section 6.2 Antibacterials including Access, Watch and Reserve Lists of antibiotics This summary has been prepared by the Health Technologies and Pharmaceuticals (HTP) programme at the WHO Regional Office for Europe. It is intended to communicate changes to the 2019 WHO Model List of Essential Medicines for adults (EML) and Model List of Essential Medicines for children (EMLc) to national counterparts involved in the evidence-based selection of medicines for inclusion in national essential medicines lists (NEMLs), lists of medicines for inclusion in reimbursement programs, and medicine formularies for use in primary, secondary and tertiary care. This document does not replace the full report of the WHO Expert Committee on Selection and Use of Essential Medicines (see The selection and use of essential medicines: report of the WHO Expert Committee on Selection and Use of Essential Medicines, 2019 (including the 21st WHO Model List of Essential Medicines and the 7th WHO Model List of Essential Medicines for Children). Geneva: World Health Organization; 2019 (WHO Technical Report Series, No. 1021). Licence: CC BY-NC-SA 3.0 IGO: https://apps.who.int/iris/bitstream/handle/10665/330668/9789241210300-eng.pdf?ua=1) and Corrigenda (March 2020) – TRS1021 (https://www.who.int/medicines/publications/essentialmedicines/TRS1021_corrigenda_March2020. pdf?ua=1). Executive summary of the report: https://apps.who.int/iris/bitstream/handle/10665/325773/WHO- MVP-EMP-IAU-2019.05-eng.pdf?ua=1.
    [Show full text]
  • CARBAPENEMASE PRODUCING Enterobacteriaceae: MOLECULAR EPIDEMIOLOGY and ASSESSMENT of ALTERNATIVE THERAPEUTIC OPTIONS
    CARBAPENEMASE PRODUCING Enterobacteriaceae: MOLECULAR EPIDEMIOLOGY AND ASSESSMENT OF ALTERNATIVE THERAPEUTIC OPTIONS By LAURA JIMENA ROJAS COY Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy Department of Microbiology and Molecular Biology CASE WESTERN RESERVE UNIVERSITY May, 2018 CASE WESTERN RESERVE UNIVERSITY SCHOOL OF GRADUATE STUDIES We hereby approve the dissertation of Laura Jimena Rojas Coy candidate for the degree of Doctor of Philosophy*. Committee Chair Dr. Arne Riestch Committee Member Dr. Liem Nguyen Committee Member Dr. Anthony Wynshaw-Boris Committee Member Dr. Robert A. Bonomo Date of Defense March 22, 2018 *We also certify that written approval has been obtained for any proprietary material contained therein. DEDICATION To my mother Maria Grelly and my father Daniel for raising me believing that with hard work I could achieve anything I set my mind to. To my loving brother Cami for constantly looking up to me, inspiring me to always do my best; and finally to my adorable little sister Angie for her infinite an unconditional love. I love you all so much. iii ACKNOWLEDGEMENTS My deepest gratitude and appreciation to my mentor, Dr. Robert A. Bonomo, for being so generous, understanding and patient and for giving me so many wonderful opportunities, in spite of not following the "traditional" path. In addition to the tremendous academic support, he has shown me by his example that humbleness, fairness and leadership is what truly makes a good scientist. To my committee members thank you for your valuable suggestions and criticisms. To everyone in the Bonomo Lab, thank you for sharing your expertise with me and, for constantly helping me, and for each and every one of your invaluable contributions to the work summarized in this dissertation.
    [Show full text]
  • Cyslabdan, a New Potentiator of Imipenem Activity Against Methicillin-Resistant Staphylococcus Aureus, Produced by Streptomyces Sp
    J. Antibiot. 61(1): 7–10, 2008 THE JOURNAL OF ORIGINAL ARTICLE ANTIBIOTICS Cyslabdan, a New Potentiator of Imipenem Activity against Methicillin-resistant Staphylococcus aureus, Produced by Streptomyces sp. K04-0144 II. Biological Activities Atsushi Fukumoto, Yong-Pil Kim, Hideaki Hanaki, Kazuro Shiomi, Hiroshi Tomoda, Satoshi O¯ mura Received: October 5, 2007 / Accepted: December 4, 2007 © Japan Antibiotics Research Association Abstract Cyslabdan produced by Streptomyces sp. K04- 0144 was found to potentiate imipenem activity against methicillin-resistant Staphylococcus aureus (MRSA). The MIC value of imipenem against MRSA was reduced from 16 to 0.015 mg/ml in combination with cyslabdan. Study on anti-MRSA activity of other typical antibiotics in combination with cyslabdan showed that the potentiating activity was limited to b-lactam antibiotics. Furthermore, among b-lactam antibiotics, the activity of carbapenems Fig. 1 Structure of cyslabdan. was most remarkably poteintiated by cyslabdan. Keywords cyslabdan, imipenem potentiator, cyslabdan including potentiation of imipenem activity methicillin-resistant Staphylococcus aureus, MRSA, against MRSA are described. Streptomyces sp. K04-0144, b-lactam Materials and Methods Introduction Materials During our screening for potentiators of imipenem activity The following materials were purchased from commercial against methicillin-resistant Staphylococcus aureus sources: Cloxacillin (ICN Biomedicals), ampicillin (Wako), (MRSA) from microbial metabolites, cyslabdan (Fig. 1) cefalexin (Wako), cefazolin (Wako), ciprofloxacin (Wako), was isolated from the culture broth of Streptomyces sp. vancomycin (Wako), tetracycline (Wako), biapenem (Meiji K04-0144. The compound has a labdane-type diterpene Seika), streptomycin (Meiji Seika), meropenem (Sumitomo skeleton connecting with an N-acetylcysteine via thioether Pharmaceuticals), panipenem (Sankyo), penicillin G linkage [1]. In this study, the biological activities of (Sigma), cefotaxime (Sigma), cefmetazole (Sigma), and S.
    [Show full text]
  • WO 2010/025328 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 4 March 2010 (04.03.2010) WO 2010/025328 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/00 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (21) International Application Number: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, PCT/US2009/055306 DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, 28 August 2009 (28.08.2009) KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (25) Filing Language: English NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (26) Publication Language: English SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 61/092,497 28 August 2008 (28.08.2008) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant (for all designated States except US): FOR¬ GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, EST LABORATORIES HOLDINGS LIMITED [IE/ ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, —]; 18 Parliament Street, Milner House, Hamilton, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, Bermuda HM12 (BM).
    [Show full text]
  • Synergistic Meropenem/Vaborbactam Plus Fosfomycin Treatment of KPC Producing K
    antibiotics Case Report Synergistic Meropenem/Vaborbactam Plus Fosfomycin Treatment of KPC Producing K. pneumoniae Septic Thrombosis Unresponsive to Ceftazidime/Avibactam: From the Bench to the Bedside Alessandra Oliva 1,† , Ambrogio Curtolo 1, Lorenzo Volpicelli 1, Francesco Cogliati Dezza 1, Massimiliano De Angelis 1, Sara Cairoli 2, Donatella Dell’Utri 3, Bianca Maria Goffredo 2, Giammarco Raponi 1 and Mario Venditti 1,*,† 1 Department of Public Health and Infectious Diseases, Sapienza University of Rome, 00185 Rome, Italy; [email protected] (A.O.); [email protected] (A.C.); [email protected] (L.V.); [email protected] (F.C.D.); [email protected] (M.D.A.); [email protected] (G.R.) 2 Biochemistry Laboratory, Department of Specialist Pediatrics, Bambino Gesù Children’s Hospital, 00165 Rome, Italy; [email protected] (S.C.); [email protected] (B.M.G.) 3 Department of Anesthesia and Critical Care Medicine, Policlinico Umberto I, 00161 Rome, Italy; [email protected] * Correspondence: [email protected] Citation: Oliva, A.; Curtolo, A.; † These authors contributed equally to this work. Volpicelli, L.; Cogliati Dezza, F.; De Angelis, M.; Cairoli, S.; Dell’Utri, D.; Abstract: Gram-negative bacilli septic thrombosis (GNB-ST) represents a subtle and often misleading Goffredo, B.M.; Raponi, G.; Venditti, condition, potentially fatal if not recognized early and requiring prolonged antimicrobial therapy and M. Synergistic Meropenem/ anticoagulation. Herein, reported for the first time, is a very challenging case of Klebsiella producing Vaborbactam Plus Fosfomycin carbapenemase (KPC)-producing K. pneumoniae (KPC-Kp) ST unresponsive to ceftazidime/avibactam Treatment of KPC Producing K.
    [Show full text]
  • Combating Carbapenem-Resistant Enterobacteriaceae
    Combating Carbapenem-Resistant Enterobacteriaceae Laurence Wright, Pharm.D. ASP Learning Series September 6, 2018 Objectives Review mechanisms for resistance in gram-negative organisms Describe the Ambler classification of β-lactamases Evaluate novel agents for the treatment of carbapenem-resistant Enterobacteriaceae (CRE) Assess the cost impact of various agents Background CRE infection is Bacteremia with CRE reported in reported in roughly CRE is associated every state 18% of LTAC with an increase in patients mortality CRE: carbapenem-resistant Enterobacteriaceae LTAC: long-term acute care Munoz-Price, LS et al. The Lancet. 2013; 13: 785-796. Mechanisms of Resistance Mukerji S, et al. Essays Biochem. 2017 Mar 3;61(1):23-35. Ambler Classification Class Description Narrow-spectrum β-lactamases (early TEM, SHV) A Extended-spectrum β-lactamases (later TEM, SHV; CTX-M) Serine cabapenemases (KPC, SME) B Metallo-β-lactamases (NDM, IMP, VIM) C Cephalosporinases (AmpC enzymes) D Oxacillinases (OXA) Bush, K. J Infect Chemother 2013;19:549–559. β-Lactamase Inhibitors Enzyme Tazobactam Avibactam Vaborbactam Narrow-spectrum Yes Yes Yes β-lactamases ESBLs Yes Yes Yes Serine cabapenemases No Yes Yes Metallo-β-lactamases No No No Cephalosporinases Variable Yes Yes Oxacillinases No Variable No ESBL: extended-spectrum β-lactamase Wong D, et al. Drugs. 2017 Apr;77(6):615-628. Ceftolozane-Tazobactam Ceftolozane is structurally similar to ceftazidime Improved steric hindrance to prevent hydrolysis mediated through AmpC β-lactamases Less impacted by porin loss Tazobactam provides activity against class A (excluding carbapenemases) and class C β-lactamases Skalweit MJ, et al. Drug Design, Development and Therapy. 2015; 9:2919-2925.
    [Show full text]